CRISPR

Kanazawa University research: Chromatin Accessibility: A new avenue for gene editing

Retrieved on: 
Friday, February 16, 2024

KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.

Key Points: 
  • KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.
  • This phenomenon known as 'chromatin accessibility' involves a privileged set of protein molecules, many of which are still unknown.
  • Now, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, led by Yusuke Miyanari, have used advanced genetic screening methods to unravel chromatin accessibility and its pathways.
  • In this study the genes identified by CRISPR screening were subjected to ATAC-see to confirm their involvement with chromatin accessibility.

Kanazawa University research: Chromatin Accessibility: A new avenue for gene editing

Retrieved on: 
Friday, February 16, 2024

KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.

Key Points: 
  • KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.
  • This phenomenon known as 'chromatin accessibility' involves a privileged set of protein molecules, many of which are still unknown.
  • Now, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, led by Yusuke Miyanari, have used advanced genetic screening methods to unravel chromatin accessibility and its pathways.
  • In this study the genes identified by CRISPR screening were subjected to ATAC-see to confirm their involvement with chromatin accessibility.

Caribou Biosciences to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, February 15, 2024

BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences:

Key Points: 
  • BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences:
    For more information and links to available webcasts, visit the Events page on Caribou’s website.
  • Webcasts will be available on the Caribou website for 30 days after the events.

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

Retrieved on: 
Thursday, February 15, 2024

and MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).

Key Points: 
  • and MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).
  • Intellia will be responsible for the design of the editing strategy and research-grade components for the investigational therapies.
  • “This collaboration provides further validation of ReCode's SORT LNP platform to deliver diverse gene editing modalities to specific cells and tissues.
  • By combining our highly synergistic technologies and capabilities, we are excited about the potential to enable a faster path for next-generation gene editing therapeutics to CF patients.”

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

Retrieved on: 
Thursday, February 15, 2024

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).

Key Points: 
  • Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF).
  • Intellia will be responsible for the design of the editing strategy and research-grade components for the investigational therapies.
  • “This collaboration provides further validation of ReCode's SORT LNP platform to deliver diverse gene editing modalities to specific cells and tissues.
  • By combining our highly synergistic technologies and capabilities, we are excited about the potential to enable a faster path for next-generation gene editing therapeutics to CF patients.”

iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology

Retrieved on: 
Thursday, February 15, 2024

BOSTON, Feb. 14, 2024 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today that New Drug Part has secured a potent anti-cancer candidate, PHAGERIA®, with broad antimicrobial activity against ETBF (Enterotoxigenic B. fragilis), a harmful microbe associated with colorectal cancer.

Key Points: 
  • iNtRON stated that following the proprietary development of the Robot Bacteriophage 2nd generation technology, additional in-vitro evolution technology was applied.
  • The Company previously secured the technology to customize and edit bacteriophage genomes as desired using tailored CRISPR/Cas technology and Random Transposon Mutagenesis in 2022.
  • Recently, the Company has advanced this technology further to develop a more potent anti-cancer candidate, PHAGERIA®.
  • This achievement is significant as it is the first instance of applying in-vitro Evolution technology to ETBF bacteriophages, demonstrating the excellence of the bacteriophage gene editing technology (CRISPR/Cas) and Robotic Bacteriophage improvement platform technology of the Company.

Nacuity Pharmaceuticals Announces Expansion of its Business Advisory Board with Appointment of Rare Disease Advocate Daniel Feller

Retrieved on: 
Wednesday, February 14, 2024

FORT WORTH, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other ocular diseases caused by oxidative stress, today announced the expansion of its business advisory board with the appointment of Daniel Feller.

Key Points: 
  • FORT WORTH, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other ocular diseases caused by oxidative stress, today announced the expansion of its business advisory board with the appointment of Daniel Feller.
  • Mr. Feller founded Talisman Licensing, a brand building agency in Melbourne, Australia, and has served as its CEO since the Company’s inception in 2007.
  • Mrs. Feller also co-founded and currently serves as the director of UsherKids Australia, an Australian-based support network for families with children diagnosed with Usher syndrome.
  • “Nacuity’s oxidative stress therapies have broad potential to treat a variety of diseases, including retinitis pigmentosa associated with Usher syndrome.

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates

Retrieved on: 
Wednesday, February 14, 2024

CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its fourth quarter and full-year 2023 financial results and operational highlights in a conference call on February 22, 2024, at 8 a.m.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its fourth quarter and full-year 2023 financial results and operational highlights in a conference call on February 22, 2024, at 8 a.m.
  • U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call.
  • All participants should ask to be connected to the Intellia Therapeutics conference call.
  • Please visit this link for a simultaneous live webcast of the call.

Europe Cell-Based Assay Market Analysis and Forecast Report 2023-2032 Featuring Merck KGaA and Lonza Group with Focus on Emerging Technologies and Applications - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 13, 2024

The "Europe Cell-Based Assay Market: Analysis and Forecast, 2023-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Cell-Based Assay Market: Analysis and Forecast, 2023-2032" report has been added to ResearchAndMarkets.com's offering.
  • This trend is further amplified by rising chronic disease prevalence and supportive government initiatives, fostering a market poised for significant expansion.
  • The European cell-based assay market is experiencing a surge, fueled by a confluence of factors.
  • The Europe cell-based assay market is anticipated to witness growth during the forecast year 2023-2032.

Pairwise Shares Updated Strategy to Deliver High-Impact Societal and Climate Benefits

Retrieved on: 
Tuesday, February 13, 2024

Pairwise is working to accelerate more of these game-changing product innovations for consumers, including seedless blackberries and pitless cherries, using CRISPR technology.

Key Points: 
  • Pairwise is working to accelerate more of these game-changing product innovations for consumers, including seedless blackberries and pitless cherries, using CRISPR technology.
  • In 2023, the company introduced the first CRISPR food to the North American market through the food service channel and a retail test market in NYC.
  • The products, leafy green blends, include highly nutritious mustard greens that Pairwise edited with CRISPR to improve the flavor, dialing down the wasabi-like pungency of the leaves.
  • “With differentiated expertise, a robust product pipeline, and proven ability to deliver, Pairwise has the potential to contribute significant improvements in global food and agriculture,” said Cam Wheeler, Partner at Deerfield Management and Pairwise Chairman of the Board.